Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Stephen E Langabeer
Focussing on CALR Variants
No abstract is available for this article. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study. References 1, , , et al., “Concordance Between Fragment Analysis and Next-Generation Sequencing in Identification of Non-Standard CALR Indels,” International Journal of Laboratory Hematology (2026).
Incidence and impact of non-canonical JAK2 p.(Val617Phe) mutations in myeloproliferative neoplasm molecular diagnostics
Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Molecular diagnosis of the myeloproliferative neoplasms
By Dr Stephen Langabeer Myeloproliferative neoplasms The classical, Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) of polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are related, clonal, hematopoietic stem cell disorders in which the malignant process leads to an excessive red cell production, platelet production and bone marrow fibrosis.
The JAK2V617F mutation and childhood type1 diabetic nephropathy?
LETTER TO THE EDITOR The JAK2V617F mutation and childhood type1 diabetic nephropathy? First published: 22 November 2023 No abstract is available for this article. REFERENCES Bader, M. S., & Meyer, S. C. (2022). JAK2 in myeloproliferative neoplasms: Still a protagonist. Pharmaceuticals, 15(2), 160. https://doi.org/10.3390/ph15020160 Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., Vandesompele, J., & Wittwer, C. T. (2009).
Dual Drivers in the Myeloproliferative Neoplasms: An Underestimation?
Skip to main page content Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software Display options No abstract available Cite Format:
Persisting with persistent thrombocytosis
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Persisting with persistent thrombocytosis
LETTER TO THE EDITOR Persisting with persistent thrombocytosis Stephen E. Langabeer, Corresponding Author Stephen E. Langabeer Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland Correspondence Stephen E. Langabeer, Cancer Molecular Diagnostics, Trinity Translational Medicine Institute, St. James's Hospital, Dublin D08 W9RT, Ireland.
BCR::ABL1 screening is not indicated in patients with splenomegaly without neutrophilia and/or basophilia
spleen haematological diseases diagnostic screening programs The underlying causes of splenomegaly are myriad and include acute, chronic and tropical infections; haematological malignancies (both acute and chronic, myeloid and lymphoid); non-neoplastic haematological conditions (thalassaemia, autoimmune haemolysis); congestive causes (cirrhosis, cardiac failure); inflammatory conditions (systemic lupus erythematosus, sarcoidosis); neoplastic causes (haemangioma, metastases) and infiltrative...
BCR::ABL1 screening is not indicated in patients with splenomegaly without neutrophilia and/or basophilia
http://orcid.org/0000-0002-6119-158XStephen E Langabeer Cancer Molecular Diagnostics, Saint James's Hospital, Dublin, Ireland Correspondence to Dr Stephen E Langabeer, Cancer Molecular Diagnostics, Saint James's Hospital, Dublin, D08 W9RT, Ireland; slangabeer{at}stjames.ie Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.
Real-world experience of BRAF V600E mutation testing in hairy cell leukaemia
Real-world experience of BRAF V600E mutation testing in hairy cell leukaemia http://orcid.org/0000-0002-6119-158XStephen E Langabeer1, David O'Brien2, Sarah McCarron1, C Larry Bacon2, Elisabeth Vandenberghe1,2 1 Cancer Molecular Diagnostics, St James's Hospital, Dublin, Ireland 2 Department of Haematology, St James's Hospital, Dublin, Ireland Correspondence to Dr Stephen E Langabeer, Cancer Molecular Diagnostics, St James's Hospital, Dublin 8, Ireland; slangabeer{at}stjames.ie Statistics from...
Quantification of atypical BCR‐ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization?
LETTER TO THE EDITOR Úna Bhreathnach, Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland Search for more papers by this author Stephen E. Langabeer, Corresponding Author slangabeer@stjames.ie orcid.org/0000-0002-6119-158X Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland Correspondence Stephen E. Langabeer, Cancer Molecular Diagnostics, Trinity Translational Medicine Institute, St. James’s Hospital, Dublin, D08 W9RT, Ireland.
Real-world experience of BRAF V600E mutation testing in hairy cell leukaemia
Real-world experience of BRAF V600E mutation testing in hairy cell leukaemia http://orcid.org/0000-0002-6119-158XStephen E Langabeer1, David O'Brien2, Sarah McCarron1, C Larry Bacon2, Elisabeth Vandenberghe1,2 1Cancer Molecular Diagnostics, St James's Hospital, Dublin, Ireland 2Department of Haematology, St James's Hospital, Dublin, Ireland Correspondence to Dr Stephen E Langabeer, Cancer Molecular Diagnostics, St James's Hospital, Dublin 8, Ireland; slangabeer{at}stjames.ie Statistics from...
Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis
Atypical chronic myeloid leukaemia (aCML) is a rare myelodysplastic/myeloproliferative (MDS/MPN) neoplasm morphologically characterised by leukocytosis, immature granulocytes in the peripheral blood (PB) and granulocytic and megakaryocytic dysplasia in the bone marrow (BM).1 Blast crisis is frequent and associated with an exceedingly poor prognosis.2 Allogeneic stem cell transplantation is the only potentially curative option but in those patients ineligible, treatment has largely relied on...
Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis
Atypical chronic myeloid leukaemia (aCML) is a rare myelodysplastic/myeloproliferative (MDS/MPN) neoplasm morphologically characterised by leukocytosis, immature granulocytes in the peripheral blood (PB) and granulocytic and megakaryocytic dysplasia in the bone marrow (BM).1 Blast crisis is frequent and associated with an exceedingly poor prognosis.2 Allogeneic stem cell transplantation is the only potentially curative option but in those patients ineligible, treatment has largely relied on...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Stephen E
Contact Stephen E, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack